TSLP gene – Talk Bio

Generate:Biomedicines Launches Global Phase 3 Trials for AI-Engineered Anti-TSLP Antibody GB-0895 in Severe Asthma

1 week ago talkbio0Tagged AI-engineered antibody, Asthma, Biomedicines, Clinical Trials, GB-0895, Generate, Phase 3, Programmable Biology, Severe (severity modifier), SOLAIRIA-1, SOLAIRIA-2, thymic stromal lymphopoietin, TSLP gene

Generate:Biomedicines; GB-0895; Phase 3 clinical trials; TSLP; thymic stromal lymphopoietin; severe asthma; AI-engineered antibody; programmable biology; SOLAIRIA-1; SOLAIRIA-2

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

1 month ago talkbio0Tagged Antibodies, Bispecific, biobucks, China, COPD, IL33 protein, human, Preclinical, Qyuns Therapeutics, Respiration Disorders, Roche (company), TSLP gene

Roche; Qyuns Therapeutics; bispecific antibody; COPD; preclinical; TSLP; IL-33; China biotech; biobucks; respiratory disease

Tezspire Shows Promise in Treating Chronic Rhinosinusitis with Nasal Polyps

1 year ago talkbio0Tagged amgen, AstraZeneca, Chronic sinusitis, Clinical Trials, CRSwNP, Inhibitor, Nasal congestion (finding), Nasal Polyps, Tezspire, TSLP gene

Tezspire, chronic rhinosinusitis with nasal polyps (CRSwNP), AstraZeneca, Amgen, WAYPOINT trial, TSLP inhibitor, nasal congestion, nasal polyps.

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

2 years ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.